A clinical trial conducted
by researchers at the Virginia G. Piper
Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic c
Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin,
produced a significant overall survival rate in patients with advanced, previously - treated
pancreatic cancercancer.